Pharmaceutical developer Avacta Group (LSE:AVCT), also known as AVCT, is one of the UK’s leading diagnostics and cancer therapies, but has seen its share price plummet by a staggering 63% in 2024. This dramatic decline has left many investors wondering what has triggered this downward spiral in the AVCT share price. So is there more pain ahead, or is there a potential opportunity here?
What went wrong?
Many of us will know the company from the development of Covid-19 lateral flow tests. However, since then, the share price has been incredibly volatile. Since the peak in 2020, when shares hit £2.74 and the market cap was £340m, the value of the company has sunk to £154m.
Several factors seem to be at play here. Many are commonplace in the biotech sector, but I still have a few major concerns.
Passive income stocks: our picks
Do you like the idea of dividend income?
The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?
If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…
Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.
What’s more, today we’re giving away one of these stock picks, absolutely free!
Avacta, like many other pre-revenue companies in the biotech sector, has yet to turn a profit. The company’s earnings per share are forecasted to decline in the coming years, which has dampened investor confidence.
The firm boasts impressive revenue growth of 34% over the past five years. However, it seems this growth might be falling short of lofty investor expectations. With enormous rallies in previous years this disappointment has naturally led to a sell-off, driving the share price down.
Business has also been hampered by difficulties in obtaining regulatory approvals for new diagnostics and therapies. Delays in securing the rights for a new antigen testing kit in May 2023 further eroded investor confidence.
The biggest red flag for me is the dilution of shares in the company, with 31% more shares outstanding than a year ago. In February 2024, the business raised funds through a share sale at a significantly discounted price. To me, this sounds like an action the company wouldn’t do unless it really had to, sending very worrying signals.
Is there hope?
While the recent performance has been undeniably bleak, there are some positive signs for Avacta. The company finally received the ISO 13485 certification last year, allowing its tests to be used in Europe. This could lead to increased sales and potentially a turnaround in fortunes.
When compared to others in the sector, the price-to-sales (P/S) ratio of 6.6 times is well below the average of 10.2 times. There is clearly a future in the technology being used here. So if a company can grow sustainably, and build a market share large enough, it could well be a winner in the long term.
Overall
The share price decline is a complex issue, requiring a decent amount of technical knowledge of the sector. The short-term outlook might seem uncertain, but the company’s progress in regulatory approvals and its potential for future growth could represent a good opportunity for patient investors. However, I think there are less complex and more lucrative investments out there, so I’ll be staying well clear for now.
